Kaul Anupma, Kumar Shashi, Bhaduaria Dharmendra, Agrawal Vinita, Sharma R K, Prasad Narayan, Gupta Amit, Kumar Rishi
Department of Nephrology and Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Saudi J Kidney Dis Transpl. 2018 Jan-Feb;29(1):101-106. doi: 10.4103/1319-2442.225198.
Reactivation of cytomegalovirus (CMV) and BK polyomavirus (BKV) can result in virus-associated tubulointerstitial nephritis in renal allografts. All those renal biopsies reported as viral cytopathic were isolated and examined by two independent renal histopathologists from our institute and classified as CMV, BKV, and CMV-BKV coinfection-associated viral cytopathic changes with confirmation through polymerase chain reaction technology in either serum or urine or both. All twenty patients were categorized as 10 in CMV, four in BKV, and six were in CMV-BKV coinfection. One patient each had received antithymocyte globulin and basiliximab as induction all patients received triple-drug immunosuppression. The mean graft survival was 69, 61, and 59 months in CMV, BKV, and CMV-BKV coinfection group, respectively. At the end of the study period, 10 (50%) patients died. 1-, 3-and 5-year patient survival was 94%, 88% and 76% among CMV group, 75%, 75% and 50% in BKV group, and 96%, 83% and 62%, in CMV-BKV coinfection group (P = 0.157). CMV and BK virus are not so common infections in postrenal transplant patients yet an important cause of graft dysfunction. Coinfection did not pose an increased risk for acute rejection or patients and death-censored and uncensored graft survival among compared groups.
巨细胞病毒(CMV)和BK多瘤病毒(BKV)的再激活可导致肾移植受者发生病毒相关性肾小管间质性肾炎。所有报告为病毒细胞病变的肾活检标本均单独取出,由我院两名独立的肾脏组织病理学家进行检查,并分类为CMV、BKV以及CMV-BKV合并感染相关的病毒细胞病变,通过血清或尿液或两者的聚合酶链反应技术进行确诊。20例患者中,CMV感染10例,BKV感染4例,CMV-BKV合并感染6例。所有患者均接受三联免疫抑制治疗,其中1例患者接受了抗胸腺细胞球蛋白和巴利昔单抗诱导治疗。CMV、BKV和CMV-BKV合并感染组的移植肾平均存活时间分别为69个月、61个月和59个月。研究期末,10例(50%)患者死亡。CMV组1年、3年和5年患者生存率分别为94%、88%和76%,BKV组分别为75%、75%和50%,CMV-BKV合并感染组分别为96%、83%和62%(P = 0.157)。CMV和BK病毒在肾移植术后患者中并非常见感染,但却是移植肾功能障碍的重要原因。合并感染在各比较组中并未增加急性排斥反应的风险,也未影响患者以及死亡截尾和未截尾的移植肾存活情况。